Literature DB >> 8489544

Susceptibility to relapsing polychondritis is associated with HLA-DR4.

B Lang1, A Rothenfusser, J S Lanchbury, G Rauh, F C Breedveld, A Urlacher, E D Albert, H H Peter, I Melchers.   

Abstract

OBJECTIVE: To determine the frequency of HLA class II antigens in Caucasian central European patients with relapsing polychondritis (RP).
METHODS: HLA class I, DR, and DQ specificities were identified in 41 patients with RP, and the frequencies were compared with those in 204 healthy, unrelated control subjects. HLA typing was performed using the standard complement-dependent microcytotoxicity assay. HLA-DR genotyping of 12 DR4-positive RP patients and 57 controls was performed by allele-specific oligonucleotide probing after amplification of genomic DNA by polymerase chain reaction.
RESULTS: A significant increase in DR4 antigen frequency was found in the patients (56.1%) as compared with that in healthy controls (25.5%) (Pcorr < 0.001). Genotyping of DR4-positive patients and controls revealed no predominance of any DR4 subtype.
CONCLUSION: There are important clinical similarities and overlaps between RP and rheumatoid arthritis (RA). In RA, the association with DR4 has been well established. Our findings show that although there is a DR4 association with RP, the situation is sufficiently distinct from that of RA to imply considerable differences in pathogenesis of the two conditions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8489544     DOI: 10.1002/art.1780360513

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  20 in total

Review 1.  Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives.

Authors:  Antonio Vitale; Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Francesco Molinaro; Mario Messina; Florenzo Iannone; Luca Cantarini
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 2.  Relapsing polychondritis: a review.

Authors:  Aman Sharma; Karthik Gnanapandithan; Kusum Sharma; Susmita Sharma
Journal:  Clin Rheumatol       Date:  2013-07-26       Impact factor: 2.980

Review 3.  Cartilage diseases.

Authors:  Yamini Krishnan; Alan J Grodzinsky
Journal:  Matrix Biol       Date:  2018-05-24       Impact factor: 11.583

4.  A novel variant of DR4 (DRB1*0421) identified in a patient with polychondritis.

Authors:  E Keller; Z Yao; A Volgger; B Lang; E D Albert
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Patients with relapsing polychondritis and previous cartilage trauma present more autoimmunity phenomena.

Authors:  C A Cañas; A R Gómez; A F Echeverri; M A Quintana-Duque; C E Toro; A Iglesias-Gamarra
Journal:  Rheumatol Int       Date:  2011-01-26       Impact factor: 2.631

6.  A new animal model for relapsing polychondritis, induced by cartilage matrix protein (matrilin-1).

Authors:  A S Hansson; D Heinegård; R Holmdahl
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 7.  Relapsing polychondritis: a description of a case and review article.

Authors:  Amr Edrees
Journal:  Rheumatol Int       Date:  2011-01-19       Impact factor: 2.631

8.  Coexisting relapsing polychondritis and sarcoidosis: an unusual association.

Authors:  Florian Pasquet; Vincent Cottin; Nadia Sivova; Julie Le Scanff; Christiane Broussolle; Pascal Sève
Journal:  Rheumatol Int       Date:  2009-08-28       Impact factor: 2.631

9.  Auricular chondritis in NOD.DQ8.Abetao (Ag7-/-) transgenic mice resembles human relapsing polychondritis.

Authors:  Veena Taneja; Marie Griffiths; Marshall Behrens; Harvinder S Luthra; Chella S David
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

10.  Relapsing polychondritis, induced in mice with matrilin 1, is an antibody- and complement-dependent disease.

Authors:  Ann-Sofie Hansson; Martina Johannesson; Lars Svensson; Kutty Selda Nandakumar; Dick Heinegård; Rikard Holmdahl
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.